There was no significant correlation between screening positive for agoraphobia and past 30 day non-prescribed benzodiazepine use (point biserial r = .13, p = .277) but screening positive for GAD and agoraphobia were highly correlated (point biserial r = .57, p < .001). The gene discussed is GAD1; the disease is agoraphobia.